https://scholars.lib.ntu.edu.tw/handle/123456789/494930
標題: | A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer | 作者: | CHIH-HSIN YANG Mok T Han B Orlando M Puri T Park K. |
公開日期: | 2018 | 出版社: | Elsevier Inc. | 卷: | 19 | 期: | 1 | 起(迄)頁: | 27-34 | 來源出版物: | Clinical Lung Cancer | 摘要: | Pemetrexed is a standard first-line treatment for advanced nonsquamous non–small-cell lung cancer (NSCLC), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a standard first-line treatment for advanced nonsquamous NSCLC with activating EGFR mutations. Pemetrexed and EGFR TKIs have different mechanisms of action and minimally overlapping toxicity profiles; therefore, it is hypothesized that their combination might result in acceptable toxicity, provided that the synergistic antitumor activity observed in preclinical studies is achieved. This review summarizes clinical trials of pemetrexed in combination with an EGFR TKI for the treatment of advanced nonsquamous NSCLC in the first- and second-line settings, using intercalated, sequential, and concurrent treatment strategies. As would be expected, such strategies were most efficacious in patients with the activating EGFR mutations associated with response to an EGFR TKI. In the studies that compared a pemetrexed-EGFR TKI combination with pemetrexed alone or the EGFR TKI alone, the pemetrexed-EGFR TKI combination was more efficacious than the single-agent regimens. The pemetrexed-EGFR TKI combinations were generally associated with a higher incidence of grade 3/4 treatment-related adverse events than the single-agent regimens; however, such toxicities were clinically manageable. Future studies of pemetrexed-EGFR TKI combinations should focus on optimizing treatment strategies in patients with activating EGFR mutations. ? 2017 The Author(s) |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85025133474&doi=10.1016%2fj.cllc.2017.06.013&partnerID=40&md5=055611080b848b908a479cc9101e643f https://scholars.lib.ntu.edu.tw/handle/123456789/494930 |
ISSN: | 1525-7304 | DOI: | 10.1016/j.cllc.2017.06.013 | SDG/關鍵字: | carboplatin; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; pemetrexed; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; pemetrexed; protein kinase inhibitor; advanced cancer; advanced nonsquamous non small cell lung cancer; cancer chemotherapy; cancer patient; gene mutation; human; non small cell lung cancer; phase 2 clinical trial (topic); phase 3 clinical trial (topic); Review; cancer staging; clinical trial (topic); genetics; lung tumor; mutation; non small cell lung cancer; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。